Endralazine

Endralazine
Clinical data
ATC code	C02DB03 (WHO) ;
Identifiers
	IUPAC name 6-benzoyl-3-hydrazinyl-5H,6H,7H,8H-pyrido[4,3-c]pyridazine;
CAS Number	39715-02-1 ;
PubChem CID	47608;
ChemSpider	43316 ;
UNII	L44741F05P;
KEGG	D08254 ;
ChEMBL	ChEMBL254193 ;
CompTox Dashboard (EPA)	DTXSID40192791 ;
Chemical and physical data
Formula	C14H15N5O
Molar mass	269.308 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1ccc(cc1)C(=O)N2CCc3c(c/c(=N/N)/[nH]n3)C2;
	InChI InChI=1S/C14H15N5O/c15-16-13-8-11-9-19(7-6-12(11)17-18-13)14(20)10-4-2-1-3-5-10/h1-5,8H,6-7,9,15H2,(H,16,18) ; Key:ALAXZYHFVBSJKZ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Endralazine is an antihypertensive of the hydrazinophthalazine chemical class.[1] It is not approved for use in the United States.

References

Meredith PA, Elliott HL, McSharry DR, Kelman AW, Reid JL (July 1983). "The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects". British Journal of Clinical Pharmacology. 16 (1): 27–32. doi:10.1111/j.1365-2125.1983.tb02139.x. PMC 1427948. PMID 6882620.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.